Findings
Regulatory inconsistencies across FDA divisions create uncertainty and inefficiencies in the approval process for digital health products.
Misalignment between FDA regulatory requirements and payer expectations hinders the commercialization and adoption of digital health innovations.
The absence of clear alternative regulatory pathways for novel digital health products discourages investment and innovation.
The lack of standardized regulatory frameworks for AI-driven healthcare technologies, including large language models (LLMs), poses challenges for industry adoption.
Limited international harmonization in digital health regulation makes it difficult for companies to scale innovations globally.

Recommendations
FDA should improve communication and coordination across divisions to ensure consistent regulatory interpretations and processes.
Regulatory pathways for novel digital health products should be modernized, including the introduction of alternative approval mechanisms tailored to iterative software development and AI-enabled devices.
A regulatory framework for third-party large language models (LLMs) should be developed to support their integration into digital health applications.
Greater alignment between FDA and payer decision-makers is needed to streamline market access and ensure reimbursement for digital health products.
International regulatory harmonization efforts should be expanded to facilitate global adoption of digital health technologies.

Regulatory Considerations
The FDA should clarify and refine regulatory requirements for AI-driven digital health products, including predefined change control plans for software updates.
Cloud-based health platforms require clear regulatory guidance on security, data ownership, and compliance with HIPAA and international privacy laws.
Real-world evidence (RWE) should be incorporated into regulatory decision-making to facilitate faster approvals and post-market surveillance of digital health products.
Standardized regulatory frameworks for digital biomarkers and digital drug development tools (DDDTs) should be developed to support clinical research applications.
Policymakers should collaborate with industry stakeholders to establish education and training programs on digital health innovation and regulatory science.